# Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy

> **NCT01676961** · PHASE2 · TERMINATED · sponsor: **NYU Langone Health** · enrollment: 5 (actual)

## Conditions studied

- Refractory Multiple Myeloma
- Stage I Multiple Myeloma
- Stage II Multiple Myeloma
- Stage III Multiple Myeloma
- Thrombocytopenia

## Interventions

- **BIOLOGICAL:** romiplostim

## Key facts

- **NCT ID:** NCT01676961
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-01
- **Primary completion:** 2015-11
- **Final completion:** 2015-11
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** PI left the institution
- **Last updated:** 2018-10-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01676961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01676961, "Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01676961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*